Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN
Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN
Active, not recruiting · NCT03386513 · Registry updated 2026-09-04Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN | CD4+/CD56+ hematodermic neoplasm, Disease Attributes, Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Recurrence, Skin and Connective Tissue Diseases, acute myeloid leukemia, bone marrow disorder, hematologic disorder, hematopoietic and lymphoid system neoplasm, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, malignant histiocytosis, myeloid leukemia, myeloproliferative neoplasm, neoplasm, skin disorder, skin neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2026-09-04 | NCT03386513 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AbbVie | 340 |
29 results · Page 1 of 2
Research sites
Swipe the table sideways for more columns.